Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

225 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Rheumatoid Arthritis NCT01166620

- 23-06-21 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics; ODM derived from: https://clinicaltrials.gov/show/NCT01166620

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - End of Double Blind - Administrative; Subject Continuation; Phase Conclusion

- 24-03-20 - 1 Formulier, 3 Itemgroepen, 7 Data-elementen, 1 Taal
Itemgroepen: Administrative, Subject Continuation, Phase Conclusion
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT01197534

- 22-01-21 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.; ODM derived from: https://clinicaltrials.gov/show/NCT01197534

Eligibility NCT00754559 Rheumatoid Arthritis - Eligibility

- 17-09-21 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00754559

Eligibility Rheumatoid Arthritis NCT00162201

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00162201

Eligibility Rheumatoid Arthritis NCT01745055

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 6 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Co-Administration Of Methotrexate And CP-690,550; ODM derived from: https://clinicaltrials.gov/show/NCT01745055

Eligibility Rheumatoid Arthritis NCT01969604

- 28-09-20 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01969604

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Log Status; Non-Serious Adverse Events; Serious Adverse Events

- 25-03-20 - 1 Formulier, 14 Itemgroepen, 102 Data-elementen, 1 Taal
Itemgroepen: Log Status, Non-Serious Adverse Event, Serious Adverse Event - Type of Report, Serious Adverse Event - Randomisation, Serious Adverse Event, Serious Adverse Event - Seriousness, Serious Adverse Event - Relevant Concomitant/ Treatment Medications, Serious Adverse Event - Relevant Medical Conditions/Risk Factors, Serious Adverse Event - Relevant Diagnostic Results, Serious Adverse Event - Rechallenge, Serious Adverse Event - Investigational Product Double Blind Phase, Serious Adverse Event - Investigational Product Open Label Phase, Serious Adverse Event - General Narrative Comments, Serious Adverse Event - Non Clinical
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT02507752

- 24-11-20 - 1 Formulier, 2 Itemgroepen, 9 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab; ODM derived from: https://clinicaltrials.gov/show/NCT02507752

Eligibility Rheumatoid Arthritis NCT01667458

- 09-02-20 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab); ODM derived from: https://clinicaltrials.gov/show/NCT01667458

Eligibility Rheumatoid Arthritis NCT02219347

- 16-04-20 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Biomarkers of Remission in Rheumatoid Arthritis (BioRRA); ODM derived from: https://clinicaltrials.gov/show/NCT02219347

Eligibility Effect Assessment Of Periodontal Prophylaxis On Patients With Anti-CCP Positive Early Rheumatoid Arthritis NCT01706874 - Eligibility Patients With Anti-CCP Positive Early Rheumatoid Arthritis NCT01706874

- 18-11-20 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.; ODM derived from: https://clinicaltrials.gov/show/NCT01706874

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial